75 related articles for article (PubMed ID: 15381161)
1. Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells.
He D; Yang H; Lin Q; Huang H
Int J Biochem Cell Biol; 2005 Jan; 37(1):192-205. PubMed ID: 15381161
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the cytotoxic effect of anti-carcinoembryonic antigen immunotoxins by adenovirus and carboxylic ionophores.
Griffin TW; Childs LR; FitzGerald DJ; Levin LV
J Natl Cancer Inst; 1987 Oct; 79(4):679-85. PubMed ID: 3498854
[TBL] [Abstract][Full Text] [Related]
3. [T lymphocytes with chimeric receptor induce carcinoembryonic antigen-positive specific gastric carcinoma cells apoptosis].
Xu HY; Xu L; Gao JH; Li KZ; Dou KF
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1053-7. PubMed ID: 17672971
[TBL] [Abstract][Full Text] [Related]
4. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
5. Antibody internalization after cell surface antigen binding is critical for immunotoxin development.
Kuo SR; Alfano RW; Frankel AE; Liu JS
Bioconjug Chem; 2009 Oct; 20(10):1975-82. PubMed ID: 19785403
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
[TBL] [Abstract][Full Text] [Related]
7. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
[TBL] [Abstract][Full Text] [Related]
9. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
10. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of anti-carcinoembryonic antigen immunotoxin cytotoxicity by monoclonal antibodies reacting with co-expressed carcinoembryonic antigen epitopes.
Byers VS; Pawluczyk I; Berry N; Durrant L; Robins RA; Garnett MC; Price MR; Baldwin RW
J Immunol; 1988 Jun; 140(11):4050-5. PubMed ID: 2453564
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
13. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
14. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
15. A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains.
Park JH; Kwon HW; Chung HK; Kim IH; Ahn K; Choi EJ; Pastan I; Choe M
Mol Cells; 2001 Dec; 12(3):398-402. PubMed ID: 11804341
[TBL] [Abstract][Full Text] [Related]
16. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells.
Hetzel C; Bachran C; Fischer R; Fuchs H; Barth S; Stöcker M
J Immunother; 2008 May; 31(4):370-6. PubMed ID: 18391759
[TBL] [Abstract][Full Text] [Related]
17. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
Erickson HA; Jund MD; Pennell CA
Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
[TBL] [Abstract][Full Text] [Related]
19. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
20. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo.
Biglari A; Southgate TD; Fairbairn LJ; Gilham DE
Gene Ther; 2006 Apr; 13(7):602-10. PubMed ID: 16397508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
